Agomab Therapeutics (AGMB) Short term Debt (2025)
Agomab Therapeutics (AGMB) posted quarterly Short term Debt of $7.6 million for Q4 2025.
Agomab Therapeutics (AGMB) Short term Debt (2025) Analysis & Trends
Agomab Therapeutics' Short term Debt history runs 1 years deep, the most recent figure standing at $7.6 million for Q4 2025.
- In Q4 2025, Short term Debt changed N/A year-over-year to $7.6 million; the TTM figure through Dec 2025 stood at $7.6 million (changed N/A YoY), while the FY2025 annual figure was $7.6 million, changed N/A from the prior year.
- Short term Debt for Q4 2025 stood at $7.6 million.
- The five-year high for Short term Debt was $7.6 million in Q4 2025, with the low at $7.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - |
| 10 | Agomab Therapeutics | 7.26 Mn | -250.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.60 Mn |